The XI Pezcoller Symposium will be held in Rovereto, Italy, from 5 - 7 June, 1999. It will be entitled “Molecular Horizons in Cancer Therapeutics” and will be focused on cutting edge approaches to the development of new ideas and methodologies in cancer therapeutics. It will include a discussion of new strategies in developing chemical knowledge and compounds of potential interest in cancer therapeutics. A session will be devoted to modern technologies used in drug discovery, new screening strategies and the identification of gene determinants of drug action. A session will be devoted to discussion of immunological and biological approaches to cancer therapeutics with particular emphasis on mechanisms of antigen presentation and of non-invasive imaging technology for the study of antiangionesis compounds. A session will be devoted to interference with signaling including the effects of small chemical inhibitors. A final session will be devoted to interference with cell regulatory function including the role of P300/CDP, E2F, F-box protein p45SKP2, the regulation of p53 and clinical studies of signal transduction inhibition.

The multidisciplinary discussions to be held at this Symposium are expected to clarify issues pertinent to the topics mentioned above. Because equal time is allocated to presentation and to discussion, opportunities are provided for intensive interactions and cross stimulation among participants. In addition to the presentation by invited speakers, there will be also a session of posters with submissions relevant to the topics discussed.
Program

June 5

8:30 Registration
9:00 Pezcoller Foundation Officers Welcome & Introductory Remarks
9:15 Enrico Mihich Focus & Goals

AM, Session I, New Chemical Strategies
Co-Chairmen: Joel Huberman and Michael Eck

9:30 Roland Burli Regulation of transcription by synthetic DNA binding ligands
10:00 Discussion
10:30 Coffee Break
11:00 Alfred Wittinghofer The GTPase reaction of Ras: A new target for anti-cancer therapy
11:30 Discussion
12:00 Ernest Laue Structure of the INK4/Cdk6 complex: Control of the G1 phase of the cell-cycle
12:30 Discussion
13:00 Lunch

PM, Session II, Drug Discovery Technologies
Co-Chairmen: Brian Leyland-Jones and Andrew Simpson

14:00 Scott Lowe Control of apoptosis and senescence by cancer genes
14:30 Discussion
15:00 Andrew Pakula New approaches for anticancer drug discovery: Affinity-based high throughput screening technology provides access to novel targets
15:30 Discussion
16:00 Rakesh Jain Non-invasive monitoring of gene expression and function in vivo
16:30 Discussion
17:00 Adjourn

June 6

AM, Session III, Biologicals
Co-Chairmen: Elizabeth Repasky and Jonathan Howard

8:30 James Allison Manipulation of T cell activation in tumor immunotherapy
9:00 Discussion
9:30 Antonio Lanzavecchia The role of dendritic cells in antigen presentation and T cell activation
10:00 Discussion
10:30 Coffee Break
11:00 Giorgio Trinchieri Proinflammatory and immune mechanisms in the antitumor effect of IL-12
11:30 Discussion
12:00  Ell Gilboa  
Immunotherapy of cancer with RNA transfected dendritic cells
12:30  Discussion
13:00  Lunch

14.00  Poster Session

**PM, Session IV, Signaling**

*Co-Chairmen:* Paul Workman and P. Giuseppe Pellicci

15:00  Paolo Comoglio  
Signal transduction for invasive growth
15:30  Discussion
16:00  Coffee Break
16:30  Frank McCormick  
Regulation of E2F and p53 in cancer cells and during viral infection
17:00  Discussion
17:30  Nicholas Lydon  
Structure-based discovery and development of selective protein kinase inhibitor drugs
18:00  Discussion
18:30  Adjourn

**June 7**

**AM, Session V, Cell Regulatory Functions**

*Co-Chairmen:* Giulio Draetta and Alex Matter

8:00  David Livingston  
P300/CDP as molecular targets
8:30  Discussion
9:00  William Kaelin, Jr  
Selective killing of cancer cells based on deregulation of E2F1
9:30  Discussion
10:00  Coffee Break
10:30  Maria Laura Avantaggiati  
Post-translational regulation of p53 by acetyltransferases: Novel targets for cancer therapy
11:00  Discussion
11:30  Wilhelm Krek  
Cell cycle control in normal and neoplastic cells: the F-box protein p45SKP2 displays its many talents
12:00  Discussion
12:30  S. Kaye  
Signal transduction inhibition, its role in cancer therapy
13:00  Discussion
13:30  Lunch
14:30  Adjourn